People used to talk about the word “compounded” when pharmacists, doctors and patients with special medical needs were in a room together. Then GLP-1 medications became hard to find. Suddenly telehealth ads were everywhere. The word compounded became a part of everyday talk almost overnight.
If you are trying to lose weight the main difference might just seem to be about money. An FDA-approved injection might cost hundreds of dollars every month. Meanwhile an online company offers what looks like the medication for a much lower price.
Those ads often look very safe. You might see terms like “compounded ” “personalized tirzepatide” or a mix of semaglutide with vitamin B12. Some of these companies even use photos and colors that look like the big prescription brands you know.
This leaves patients with a fair question: if both products have semaglutide in them how much of a difference can there actually be?
The truth is, they can be very different.
Compounded medications do have a place in healthcare. Pharmacists make compounded medications every day for patients who cannot use the products available on the market. However, a compounded medication is not an FDA-approved drug. A compounded medication is also not automatically the same as a brand-name or generic medicine.
This difference changes how a product is tested, made, labeled, prescribed and watched. When it comes to injectable GLP-1 medications this difference can change how much a patient can trust what is actually inside the vial and how much of the dose they should inject.
What is a compounded medication?
Compounding means making a medication for a medical need by mixing, diluting or changing ingredients.
Think about a child who needs a drug that only comes in a pill but cannot swallow. A pharmacist can make a version through compounding.. Think about a patient who is allergic to a certain dye in a regular pill. That patient might need a capsule made without that ingredient. Someone who needs an unusual dose might also benefit from a compounded medication.
These are not tricks or weird uses. These are the reasons why pharmacy compounding exists.
Compounding can also help when there is a drug shortage. If an FDA-approved medicine is not available and meets legal rules pharmacies might temporarily make compounded versions so patients do not lose their treatment.
That is what happened when the demand for semaglutide and tirzepatide was higher than the supply. Ozempic, Wegovy, Mounjaro and Zepbound became names everyone knew. Many people could not actually get their prescriptions filled. Compounding grew to help fill that gap.
The shortage was real. The need was real too.
Things got messy after that. Compounded GLP-1 treatment went from being a way to help with a shortage to a massive business selling to people online. When the supply of approved products got better ads, for cheap “generic” or “same ingredient” injections kept popping up.
That kind of talk can hide a boundary that patients really need to see.
Compounded does not mean generic
This is probably the most common misunderstanding.
A generic medicine is approved by the FDA. The manufacturer of a generic drug must prove that it meets the approved criteria for the reference listed drug and that it works in the same way in the body to produce similar therapeutic results.
A compounded medicine is not an FDA-approved generic.
The FDA has not reviewed the formula for the compounded medication. Therefore, the compounded medication has not gone through the FDA’s process of determining whether the final product is of the proper strength, remains stable for the appropriate amount of time, produces the expected clinical effect, and is manufactured with consistent quality control from batch to batch.
The amount of evidence supporting the safety of a compounded medication, as well as the regulatory oversight provided for these medications, is vastly different from that of an approved medication distributed through the formal FDA approval process.
A pharmacist can make one capsule with dye-free ingredients for a single patient in a pharmacy. But that does not mean the same pharmacist can manufacture generic tablets to be distributed to millions of patients as part of an FDA-approved generic drug.
A major problem occurs when a pharmacy-compounded medication is promoted as if it went through the same process as an FDA-approved generic medication.
Using terms such as “generic Ozempic” or “like Wegovy” to market a compounded version of semaglutide can be very misleading to patients.
They may believe they are receiving a generic version of a brand-name medication that has gone through the same approval process required for an FDA-approved generic. That is not the case.
What FDA approval actually adds
FDA approval does not equal safety. Ozempic, Wegovy, Mounjaro, and Zepbound can still have adverse effects if improperly manufactured or used.
Approval means that they’ve analyzed the evidence on the product, its dose, formulation, manufacturing process, and the medical application. The normal process includes clinical studies on the drug, chemistry and manufacturing data, stability studies, inspecting pharmaceutical companies, standardized labeling, and post-approval monitoring.
Approved injectable GLP-1 drugs come in specific devices or presentations with exact concentrations. The patient gets the dose instructions based on the product.
The compounded versions can be in multidose vials, pre-filled syringes, or other presentations, that may vary from pharmacy to pharmacy. The concentration may also be different.
A pharmacy can prepare a vial with a specific concentration of semaglutide. The other one prepares a more potent version and provides completely different instructions. The patient may get an advice to inject a certain number of “units” of the medication, while the prescription says 1 milligram.
The dosing problem with compounded GLP-1 injections
A patient is unlikely to reason in terms of milligrams per milliliter. They will most probably think in terms of the line on the syringe to reach the indicated dose.
As such, it is crucial to make sure that they get the right dose in the syringe. It is entirely possible that the patient receives the wrong dose when switching from one telehealth provider to another. One vial may have a syringe with a different concentration than the previous one. If the last month’s dose was 20 units, this month’s 20 units may be substantially higher.
It is not that the number on the syringe has changed; it is the amount of medication in it.
The FDA has received reports (including adverse event reports from patients and healthcare professionals) of medication errors due to the conversion between milligrams, milliliters, and units. It appears that patients injected themselves with five or ten times more medication than prescribed. The aftermath of such medication errors has been severe, including vomiting, nausea, abdominal pain, diarrhea, dehydration, syncope, pancreatitis, and cholelithiasis. Some patients had to be hospitalized for these complications.
It is not that all compounded preparations of GLP-1 analogs would be incorrectly dosed; it is that it is relatively easy to make a mistake when concentrations, containers, and labels are different. A pen with a prefilled dose eliminates the possibility of measuring errors. A multidose vial requires a syringe to withdraw the required amount of insulin-like substance.
I can handle a syringe; not everyone can. Someone who has been injecting themselves for months will have no problem with drawing the dose; someone who had to receive the injection for the first time will.
If a compounded medicine is prescribed, the pharmacist should physically or visually demonstrate the dose. The patient should be able to answer four questions before the first injection:
- What is my dose in milligrams?
- What is the concentration inside this particular vial?
- How many milliliters or syringe units should I inject?
- Will those instructions change when I receive my next vial?
“Take as directed” is not enough when a mistake can multiply the intended dose several times over.
Are compounded GLP-1 medications still legal?
The short answer is that while compounding is legal, the production of large quantities of copies of commercially available GLP-1 drugs is significantly limited due to the end of the shortage.
Semaglutide injections were delisted from the FDA’s drug shortage list in February 2025, and the shortage of tirzepatide was resolved earlier. In addition, during the period of transitions, the FDA allowed compounders extra time to adapt their processes without disrupting patients’ treatment.
At the same time, the FDA stated in April 2026 that the routine production of “products that are substantially similar to FDA-approved drugs” is no longer eligible for the same exceptions regarding shortages.
This does not mean that every single instance of the individual preparation of a drug became illegal.
According to section 503A of the Federal Food, Drug, and Cosmetic Act, a pharmacy or a physician can compound a drug for an individual patient with a valid prescription in case of following the appropriate instructions.
The individualization of the drug is also possible when the prescriber considers that a change in the drug’s form or ingredients is necessary to achieve a different clinical effect.
It is important to note that the individual patient’s needs, rather than the desires of a business, must be the reason for the alteration of the commercial product.
The outsourcing facilities that operate under section 503B of the FD&C Act follow a separate set of regulations. These facilities register their products with the FDA; register as outsourcing facilities; and follow the standard of the current good manufacturing practices, but their preparations are not FDA-approved products.
According to the draft guidance released by the FDA in April 2026, semaglutide, tirzepatide, and liraglutide will no longer be included in the list of substances that may be used in the bulk manufacturing by 503B facilities in accordance with clinical needs. At the time of publication, the FDA noted that there was no clinical justification for the inclusion of these substances at the moment.
The individual preparation of a drug or its compounding in the larger quantities is a significantly complex procedure, and the guidance serves only as a reminder that the individualization of the drug is not justified by the availability of another product on the market, let alone a cheaper one. In practice, this means that patients who receive these drugs should ask themselves why they have been prescribed a compounded preparation and which facility was responsible for it in case an FDA-approved alternative is available.
What are 503A and 503B pharmacies?
These statistics may seem intimidating, but there is a significant difference, which is crucial to recognize.
A 503A compounding pharmacy usually provides a medicine prepared for a specific patient in accordance with the instructions given by the doctor. This method is mainly subject to the oversight of state boards of pharmacy, with several regulatory elements nonetheless coming from the federal side.
In the meantime, a 503B facility is an outsourcing organization, which engages in wholesale compounding for health care organizations.
Such facilities require registration with the Food and Drug Administration and have to apply current good manufacturing practices, including mandatory FDA inspections, which are carried out via a risk-based approach. It is vital to note that neither of the two facilities above is fully FDA-approved, but represents a specific standard, which the compounding facilities apply.
When it comes to a 503B facility, there is a substantial likelihood that the manufacturer possesses higher level federal manufacturing requirements to address the public health, but the products made are not officially approved by the FDA. Additionally, when the telehealth company is the one to prescribe, receive, and ship a medication, the company name can be found at a website, but this organization’s name has little to do with the actual pharmacy, physician, practice responsible for prescriptions, platform which provided marketing materials, etc. Thus, it is the central prerogative for pharmacies to define and disclose the responsible party in each of the cases, informing patients of the various facets and parties involved.
The ingredients may not be exactly what you expect
The compounds in approved Ozempic and Wegovy are the base form of semaglutide used in their respective formulations. However, the FDA warns that some compounded products may use semaglutide sodium or semaglutide acetate.
Salt forms of the compound are not the same active ingredients as those in the branded medications, and the FDA has warned that it has no legal basis to use these salt forms for compounding. The agency also warns that it has no information indicating their chemical and pharmacological equivalence to semaglutide approved by the FDA. This is not a semantic difference, but a significant one.
A website may use “semaglutide” throughout its sales page, but provide little information about what substance was provided to the compounding pharmacy before purchasing the item. Before purchasing, check to ensure that the formula is not salt-based.
Another red flag is the phrase “research use only” or “not for human consumption” attached to a product that is clearly being sold with human dosing instructions. Peptides purchased from chemical suppliers do not constitute an appropriate substitute for prescription medication.
The same caution applies to retatrutide and cagrilintide. These investigational drugs have not been approved by the FDA and the FDA says they cannot legally be used for compounding under federal law. Retatrutide has received much press attention due to its impressive weight-loss trial results, but those promising research results do not make it an approved pharmacy product. Our guide to retatrutide for weight loss discusses where the research stands on the drug without treating it as an approved commercial therapy.
Quality depends on more than the active ingredient
Even in the case where the vial contains the expected substance, there are other factors to consider.
A sterile environment is needed when preparing the injection, and improper preparation could lead to bacterial or fungal contamination, which could be dangerous in the case of an injection. The medication should also have the correct concentration, proper storage conditions, reliable transport, and a reasonable beyond-use date.
In the case of injectable forms of GLP-1 hormones, temperature plays a significant role. The Food and Drug Administration received complaints that the patients were given products that were too warm upon arrival with improperly used cooling materials.
A delivery that has been left in the sun on the floor of an apartment building waiting for the residents to arrive should not be treated as business as usual. Warming of the medication that was supposed to be kept cold is not something that can simply be fixed by placing the delivered product in the refrigerator. Instead, the patient should contact the dispensing pharmacy and ask for their recommendations in such cases.
The patients who order medications through an online platform should also be able to ask for the name of the pharmacy, speak to a pharmacist, obtain the necessary information about the product, and ensure that optimal shipping conditions are used for their chosen method of delivery. A website that takes money without asking for a prescription or any form of medical screening is not a convenience, but the opposite of one.
Compounding is not the villain
It would be unfair and incorrect to suggest otherwise.
A competent professional can provide a solution to a problem that a commercial product cannot. There are patients for whom the only feasible option is a compounded liquid, a dye-free capsule, a topical ointment, or an uncommon dosage.
There is also the matter of unneeded compounding.
If an FDA-approved drug is available and suitable for a patient, there is no need to prescribe an unapproved alternative, with all the potential additional risks of potency, sterility, labeling accuracy, stability, or ingredient source.
The matter of cost is not irrelevant to this discussion; the implication that patients have no issue paying more for one product while not the other conveniently ignores the reason for the preference for compounded GLP-1s. The insurance companies have stopped covering the costs of the branded drug, leaving the patient to pay out-of-pocket for an unaffordable sum.
However, the mere fact that something costs less does not make it somehow indistinguishable from the other. A competent professional would talk to the patient about the risks of both options and their respective costs instead of burying the necessary information about one under unsubstantiated claims about the other.
When to seek medical help
Nausea, constipation, diarrhea, and loss of appetite may happen with both approved and compounded GLP-1 medicines. These symptoms warrant closer attention when they are severe, persistent, or suspected to arise from an incorrect dosage.
Contact the prescriber immediately if you cannot retain fluids, experience persistent vomiting, feel lightheaded, or suspect that you may have injected an excessive dosage.
Sudden, severe pain in the upper abdomen that radiates to the back may also require emergency intervention. So may signs of dehydration, mental confusion, very low levels of sugar in the blood, an allergic reaction, or symptoms of gallbladder disease.
Do not attempt to “cancel out” an excessive dose at home since this drug has a prolonged duration of action within the body and may necessitate continuous monitoring and supportive treatment.
Other seemingly unrelated changes may also warrant discussion. Rapid weight loss, reduction in protein consumption, and nutrient depletion may contribute to cachexia (wasting syndrome) in some individuals. Our pharmacist-reviewed examination into whether Ozempic can cause hair loss explores this issue in greater detail.
What should current compounded-GLP-1 patients do?
Do not discontinue the prescribed medication of your own accord due to a frightening headline.
First, ascertain what it is you’re being dispensed. Check the label. Call the pharmacy that dispensed it. Ask the prescriber why the compounded version remains indicated now that approved products have become available.
Some patients may have a documented indication for a custom-mixed preparation. Some patients are going to learn their telehealth company writes those are the only options because that’s where they got their prescription, or because that’s how they wrote the program.
The next step will not be the same for every patient. Some may need to stay on their current course under supervision, or transition to an approved medication, or have their dose adjusted, or discuss a different weight-management modality.
What should not happen is vial renewal of something nobody can explain.
Approved and compounded preparations can come from the same pharmacy. They can be prescribed by the same clinician. They can contain the same “active” ingredient.
They are not the same category of medicine.
Compounding is a process of creating a personalized pharmaceutical preparation to meet a specific medical need. FDA approval is a rigorous scientific and regulatory process for a specific drug product, with specific labeling and manufacturing instructions. They are not “the same thing,” not even a little bit, even if an ad uses the same molecular name.
This distinction is not meant to frighten patients away from pharmacists. It is meant to help patients ask better questions before their next bottle is ready.
